Ju Hyeon Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ju Hyeon Shin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Jong Hee Shin
Department of Laboratory Medicine, Green Cross Laboratories, Gwangju, Korea
4 shared publications - Eun Jeong Won
Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications - Dain Lee
Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea
2 shared publications - Hyun-Seung Lee
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications - Hyun-Woo Choi
Department of Laboratory Medicine, Chonnam National University Hospital and Medical School, Gwangju, Korea
2 shared publications - Mi-Ae Jang
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (5) , 422-434
Genotype-Driven Prognostication in Dilated Cardiomyopathy
Hong D, et al. Korean Circ J. 2025 Nov;56:e28. https://doi.org/10.4070/kcj.2025.0216
- 1 January 2026
- Published by XMLink in Korean Circulation Journal
- Vol. 56 (5) , 422-434
Open AccessGenotype-Driven Prognostication in Dilated Cardiomyopathy
Hong D, et al. Korean Circ J. 2025 Nov;56:e28. https://doi.org/10.4070/kcj.2025.0216
- Open Access
- 1 April 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (5) , 666-674
Reassessment of FBN1 variants of uncertain significance using updated ClinGen guidance for PP1/BS4 and PP4 criteria
Marfan syndrome (MFS) is a genetic disorder caused by an FBN1 variant and is diagnosed based on the revised Ghent criteria, which incorporate clinical manifestations and genetic testing. Up-to-date FBN1 variant interpretation is crucial for proper diagnosis and management of MFS; however, some FBN1 variants of uncertain significance (VUSs) remain inconclusive despite applying Clinical Genome Resource (ClinGen) FBN1-specific guideline. Recently, the ClinGen guidance for PP1/BS4 co-segregation and PP4 phenotype specificity criteria (new PP1/PP4 criteria) were released. Here, we performed reassessment of FBN1 VUSs using these new PP1/PP4 criteria. FBN1 VUSs collected from December 2015 to April 2024 were reassessed according to the ClinGen FBN1-specific guideline and new PP1/PP4 criteria. Medical records and previous studies were reviewed to evaluate the phenotype-specificity of evidence based on the revised Ghent criteria. Collectively, 927 patients with suspected MFS underwent FBN1 sequencing and 72 VUSs were detected. When applying the FBN1-specific guideline only, of 72 VUSs, 29 (40.3%) were reclassified as pathogenic variants (PVs) or likely PVs (LPVs). When additionally applying the new PP1/PP4 criteria, 16 (37.2%) of the remaining 43 VUSs were reclassified as LPVs. After reassessing FBN1 VUSs according to the new PP1/PP4 criteria, the rate of reclassification from VUS to PV/LPV significantly increased from 40.3% to 62.5%. The new PP1/PP4 criteria provide sufficient evidence for evaluating the pathogenicity of FBN1 variants detected in MFS patients fulfilling the revised Ghent criteria and will be helpful in clinical analysis.
- 1 April 2025
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 33 (5) , 666-674
Open AccessReassessment of FBN1 variants of uncertain significance using updated ClinGen guidance for PP1/BS4 and PP4 criteria
Marfan syndrome (MFS) is a genetic disorder caused by an FBN1 variant and is diagnosed based on the revised Ghent criteria, which incorporate clinical manifestations and genetic testing. Up-to-date FBN1 variant interpretation is crucial for proper diagnosis and management of MFS; however, some FBN1 variants of uncertain significance (VUSs) remain inconclusive despite applying Clinical Genome Resource (ClinGen) FBN1-specific guideline. Recently, the ClinGen guidance for PP1/BS4 co-segregation and PP4 phenotype specificity criteria (new PP1/PP4 criteria) were released. Here, we performed reassessment of FBN1 VUSs using these new PP1/PP4 criteria. FBN1 VUSs collected from December 2015 to April 2024 were reassessed according to the ClinGen FBN1-specific guideline and new PP1/PP4 criteria. Medical records and previous studies were reviewed to evaluate the phenotype-specificity of evidence based on the revised Ghent criteria. Collectively, 927 patients with suspected MFS underwent FBN1 sequencing and 72 VUSs were detected. When applying the FBN1-specific guideline only, of 72 VUSs, 29 (40.3%) were reclassified as pathogenic variants (PVs) or likely PVs (LPVs). When additionally applying the new PP1/PP4 criteria, 16 (37.2%) of the remaining 43 VUSs were reclassified as LPVs. After reassessing FBN1 VUSs according to the new PP1/PP4 criteria, the rate of reclassification from VUS to PV/LPV significantly increased from 40.3% to 62.5%. The new PP1/PP4 criteria provide sufficient evidence for evaluating the pathogenicity of FBN1 variants detected in MFS patients fulfilling the revised Ghent criteria and will be helpful in clinical analysis.
- Open Access
- 1 March 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (2) , 214-220
Performance Evaluation of VITEK MS for the Identification of a Wide Spectrum of Clinically Relevant Filamentous Fungi Using a Korean Collection
Ju Hyeon Shin, M.D., Soo Hyun Kim, M.D., Dain Lee, M.S., Seung Yeob Lee, M.D., Sejong Chun, M.D., Jun Hyung Lee, M.D., Eun Jeong Won, M.D., Hyun Jung Choi, M.D., Hyun Woo Choi, M.D., Seung Jung Kee, M.D., Myung Geun Shin, M.D., and Jong Hee Shin, M.D.. Ann Lab Med 2021;41:214-20. https://doi.org/10.3343/alm.2021.41.2.214
- 1 March 2021
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 41 (2) , 214-220
Open AccessPerformance Evaluation of VITEK MS for the Identification of a Wide Spectrum of Clinically Relevant Filamentous Fungi Using a Korean Collection
Ju Hyeon Shin, M.D., Soo Hyun Kim, M.D., Dain Lee, M.S., Seung Yeob Lee, M.D., Sejong Chun, M.D., Jun Hyung Lee, M.D., Eun Jeong Won, M.D., Hyun Jung Choi, M.D., Hyun Woo Choi, M.D., Seung Jung Kee, M.D., Myung Geun Shin, M.D., and Jong Hee Shin, M.D.. Ann Lab Med 2021;41:214-20. https://doi.org/10.3343/alm.2021.41.2.214
- Open Access
- 31 March 2020
- Published by Korean Society for Medical Mycology in Korean Journal of Medical Mycology
- p. 10-16
A Multicenter Study of Antifungal Use and Species Distribution and Antifungal usceptibilities of Candida Isolates in South Korea
Background: Candidiasis control should include monitoring the epidemiology and resistance to various antifungal agents. In this study, the researchers investigated the Candida species recovered from clinical specimens at particular geographic areas or hospitals. Objective: The present study is geared toward the evaluation of antifungal drug usage at Korean hospitals in 2016. It is also essential that species distribution and antifungal susceptibilities of Candida isolates should be looked into to provide important data that can help devise therapeutic strategies to control the disease. Methods: Systemic antifungal agent usage over a one-year period was investigated at 10 Korean hospitals. Identification and antifungal susceptibility tests were performed on clinical isolates of the Candida species, which were collected over a three-month period. Results: The total antifungal usage in each hospital ranged from 7.7 to 158.9 defined daily doses (DDDs) per 1,000 patient days. Fluconazole was most commonly used (37.1%), followed by amphotericin B (30.6%), itraconazole (9.7%), echinocandins (8.8%), voriconazole (7.5%), and posaconazole (6.3%), respectively. Among 274 Candida isolates, C. albicans was the most frequently recovered (51.1%), followed by C. glabrata (15.7%), C. tropicalis (15.0%), and C. parapsilosis (13.5%), respectively. Through the application of either species-specific clinical breakpoints or epidemiological cutoff values to Candida isolates, the non-susceptibility rates to fluconazole, voriconazole, amphotericin B, and micafungin were found in 20.7%, 5.6%, 0%, and 0% of isolates, respectively. Conclusion: This nationwide multicenter study showed that total antifungal use varied considerably according to each hospital. Non-susceptibility to fluconazole should be further monitored, considering the drug's frequent use in Korea.
- 31 March 2020
- Published by Korean Society for Medical Mycology in Korean Journal of Medical Mycology
- p. 10-16
Open AccessA Multicenter Study of Antifungal Use and Species Distribution and Antifungal usceptibilities of Candida Isolates in South Korea
Background: Candidiasis control should include monitoring the epidemiology and resistance to various antifungal agents. In this study, the researchers investigated the Candida species recovered from clinical specimens at particular geographic areas or hospitals. Objective: The present study is geared toward the evaluation of antifungal drug usage at Korean hospitals in 2016. It is also essential that species distribution and antifungal susceptibilities of Candida isolates should be looked into to provide important data that can help devise therapeutic strategies to control the disease. Methods: Systemic antifungal agent usage over a one-year period was investigated at 10 Korean hospitals. Identification and antifungal susceptibility tests were performed on clinical isolates of the Candida species, which were collected over a three-month period. Results: The total antifungal usage in each hospital ranged from 7.7 to 158.9 defined daily doses (DDDs) per 1,000 patient days. Fluconazole was most commonly used (37.1%), followed by amphotericin B (30.6%), itraconazole (9.7%), echinocandins (8.8%), voriconazole (7.5%), and posaconazole (6.3%), respectively. Among 274 Candida isolates, C. albicans was the most frequently recovered (51.1%), followed by C. glabrata (15.7%), C. tropicalis (15.0%), and C. parapsilosis (13.5%), respectively. Through the application of either species-specific clinical breakpoints or epidemiological cutoff values to Candida isolates, the non-susceptibility rates to fluconazole, voriconazole, amphotericin B, and micafungin were found in 20.7%, 5.6%, 0%, and 0% of isolates, respectively. Conclusion: This nationwide multicenter study showed that total antifungal use varied considerably according to each hospital. Non-susceptibility to fluconazole should be further monitored, considering the drug's frequent use in Korea.
- Open Access
- 15 October 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (8) , 1074
Erratum: XBP1S Regulates MUC5B in a Promoter Variant–Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway Epithelia
- 15 October 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (8) , 1074
Open AccessErratum: XBP1S Regulates MUC5B in a Promoter Variant–Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway Epithelia
- Open Access
- 15 October 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (8) , 1073-1074
Reply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections
- 15 October 2019
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 200 (8) , 1073-1074
Open AccessReply to Aubry and Veziris: Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections